Inhibrx Biosciences, Inc. (INBX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Inhibrx Biosciences reported revenue of $1.3M, up 550.0% from $200,000 the year before. Net income was -$140.1M (a -10773.5% net margin), or -$9.04 per diluted share. Operating margin was -10386.5%. Operating activities generated -$129.8M of cash, leaving -$129.8M of free cash flow. At fiscal year end, Inhibrx Biosciences held $146.5M in total assets against $138.5M in total liabilities, including $124.2M of cash and equivalents.
Open the full interactive Inhibrx Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Inhibrx Biosciences Key Stats
| Share Price | $87.08 |
|---|---|
| Market Cap | $1.36B |
| Revenue YoY Growth | +550.0% |
| 52-Week Range | $28.36 – $141.84 |
| Shares Outstanding | 15.7 million (basic, 2026 Q2) |
Inhibrx Biosciences Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $200,000 | $1.3M |
| Operating Income | -$331.4M | -$135.0M |
| Pre-Tax Income | $1.69B | -$140.1M |
| Income Tax | $2,000 | $2,000 |
| Net Income | $1.69B | -$140.1M |
| Diluted EPS | $112.62 | -$9.04 |
Inhibrx Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$35.3M | -$32.8M | -$33.4M | -$36.6M |
| Diluted EPS | -$2.28 | -$2.12 | -$2.15 | -$2.34 |
Inhibrx Biosciences Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $152.6M | $124.2M |
| Current Assets | $160.4M | $132.8M |
| Total Assets | $180.8M | $146.5M |
| Current Liabilities | $40.7M | $33.8M |
| Total Long-Term Debt | — | $100.6M |
| Total Liabilities | $47.2M | $138.5M |
| Shareholders' Equity | $133.6M | $8.0M |
Inhibrx Biosciences Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$194.4M | -$129.8M |
| Cash From Investing | -$2.6M | -$28,000 |
| Cash From Financing | $71.7M | $101.4M |
| Free Cash Flow | -$197.0M | -$129.8M |
Figures from Inhibrx Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Inhibrx Biosciences financials page for every line item.
Inhibrx Biosciences Company Profile
| Ticker | INBX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | La Jolla, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0002007919 |
Frequently Asked Questions
What was Inhibrx Biosciences' revenue in fiscal 2025?
Inhibrx Biosciences (INBX) reported revenue of $1.3M for fiscal 2025.
What was Inhibrx Biosciences' net income in fiscal 2025?
Inhibrx Biosciences reported net income of -$140.1M for fiscal 2025.
What was Inhibrx Biosciences' earnings per share (EPS) in fiscal 2025?
Inhibrx Biosciences' diluted EPS was -$9.04 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Inhibrx Biosciences generate in fiscal 2025?
Inhibrx Biosciences generated -$129.8M of free cash flow in fiscal 2025.
What was Inhibrx Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Inhibrx Biosciences reported revenue of $0.
How much debt does Inhibrx Biosciences have?
Inhibrx Biosciences reported $100.6M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Inhibrx Biosciences are outstanding?
Inhibrx Biosciences reported a weighted average of 15.7 million basic shares outstanding in 2026 Q2.
What is Inhibrx Biosciences' market cap?
Based on its latest closing price, Inhibrx Biosciences (INBX) has a market capitalization of about $1.36B.
When does Inhibrx Biosciences' fiscal year end?
Inhibrx Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Inhibrx Biosciences headquartered?
Inhibrx Biosciences lists its business address in La Jolla, California in its SEC filings.
Inhibrx Biosciences Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →